| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 06/26/2002 | CN1355705A Method of identifying therapeutic compounds for treatment of hepatic disorders |
| 06/26/2002 | CN1355698A Compound for medicine for treating function of bronchial contraction |
| 06/26/2002 | CN1355690A Method for improving half-life of soluble viral-specific ligands on mucosal membranes |
| 06/26/2002 | CN1355689A Methods for regulating condition of mammalian keratinous tissue |
| 06/26/2002 | CN1086579C Oral formulations of antifungal |
| 06/25/2002 | US6410688 Def1 |
| 06/25/2002 | US6410599 Mixture of benzalkonium chloride, water and isopropanol |
| 06/25/2002 | US6410595 Methods and compositions for treating male erectile dysfunction |
| 06/25/2002 | US6410589 Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of disease |
| 06/25/2002 | US6410577 Administered as anorexigenic agents, dietetics, antidiabetics and for enhancing lipid metabolism |
| 06/25/2002 | US6410575 Administering (5-aryl-1,2,4-thiadiazol)-3-yl thiourea and urea derivatives to treat hepatitis, hiv and kaposi sarcoma, as viricides and anticarcinogenic agents |
| 06/25/2002 | US6410570 Using carboxylated pyridine complex |
| 06/25/2002 | US6410556 Antidiabetic agents |
| 06/25/2002 | US6410554 Adrenergic antagonist |
| 06/25/2002 | US6410546 Aids therapy |
| 06/25/2002 | US6410544 Vision defects; administering pilocarpine |
| 06/25/2002 | US6410540 Inhibitors of p38-αkinase |
| 06/25/2002 | US6410524 Concurrent administering |
| 06/25/2002 | US6410512 Inhibitors of proteasomal activity for stimulating hair growth |
| 06/25/2002 | US6410328 Sensitizing cells to compounds using lipid-mediated gene and compound delivery |
| 06/25/2002 | US6410289 Isolated human dehydrogenases, nucleic acid molecules encoding these human dehydrogenases, and uses thereof |
| 06/25/2002 | US6410263 Histidine kinase |
| 06/25/2002 | US6410255 Optical probes and assays |
| 06/25/2002 | US6410250 Sustained delivery device and methods of making and using the same |
| 06/25/2002 | US6410249 Odorant receptors |
| 06/25/2002 | US6410245 Complexing; fusion proteins; quantitative analysis |
| 06/25/2002 | US6410061 Tea catechins as cancer specific proliferation inhibitors |
| 06/25/2002 | US6410059 Pharmaceutical composition containing cow urine distillate and an antibiotic |
| 06/25/2002 | US6410052 Tea catechins in sustained release formulations as cancer specific proliferation inhibitors |
| 06/25/2002 | US6410043 Method for chemoprevention of prostate cancer |
| 06/25/2002 | US6410041 Culturing cells in presence of amphipathic weak bases and/or cations and multiple drug resistance inhibitor containing reserpine |
| 06/25/2002 | US6410019 Topical administration of immunoglobulins brings about remission of inflammatory process without causing any toxic or unwanted side effects |
| 06/25/2002 | US6410007 Erectile dysfunction, vasodilation |
| 06/25/2002 | CA2245462C Methods of modulating cell proliferation through telomerase modulation |
| 06/25/2002 | CA2217952C A pharmaceutical composition containing benzimidazole for inhibiting the growth of cancers |
| 06/25/2002 | CA2201587C Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
| 06/25/2002 | CA2135648C Therapy and diagnosis of conditions related to telomere length and/or telomerase activity |
| 06/25/2002 | CA2071981C The use of gaba-b selective agonists as anti-tussive agents |
| 06/22/2002 | CA2365673A1 Methods, compositions and kits relating to cardiovascular disease |
| 06/20/2002 | WO2002048715A2 Inflammatory markers for detection and prevention of diabetes mellitus |
| 06/20/2002 | WO2002048388A2 Method of inhibiting infection by hcv, other flaviviridae viruses, and any other virus that complexes to low density lipoprotein or to very low density lipoprotein in blood preventing viral entry into a cell |
| 06/20/2002 | WO2002048368A2 Proteins associated with cell growth, differentiation, and death |
| 06/20/2002 | WO2002048366A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 06/20/2002 | WO2002048365A2 Isolated human transporter proteins, nucleic acid molecules encoding human transporter proteins, and uses thereof |
| 06/20/2002 | WO2002048363A2 Human transporter proteins, nucleic acid molecules encoding them, and uses thereof |
| 06/20/2002 | WO2002048358A2 Regulation of human chemokine-like receptor |
| 06/20/2002 | WO2002048348A1 Novel gene existing in human leukocyte antigen domain |
| 06/20/2002 | WO2002048337A2 Secreted human proteins |
| 06/20/2002 | WO2002048172A2 Diaryl peptides as ns3-serine protease inhibitors of hepatits c virus |
| 06/20/2002 | WO2002048171A1 Methylene steroids as novel androgens |
| 06/20/2002 | WO2002048167A1 Method for generating immortal dendritic cell lines |
| 06/20/2002 | WO2002048165A2 Antiviral agents for treatment of flaviviridae infections |
| 06/20/2002 | WO2002048131A1 Arylated furane and thiophene carboxylic acid amides with potassium channel blocking effect |
| 06/20/2002 | WO2002048122A2 Benzamidine derivatives |
| 06/20/2002 | WO2002047731A2 Drug delivery compositions and coated medical devices |
| 06/20/2002 | WO2002047728A2 Treatment of posterior capsule opacification |
| 06/20/2002 | WO2002047726A2 Pharmaceutical composition containing an active with a hemolytic action and a surfactant |
| 06/20/2002 | WO2002047721A1 Silensed anti-cd28 antibodies and use thereof |
| 06/20/2002 | WO2002047712A2 Peptide yy and peptide yy agonists for treatment of metabolic disorders |
| 06/20/2002 | WO2002047708A2 Selective cox-2 inhibition from edible plant extracts |
| 06/20/2002 | WO2002047684A1 Methof for treatment of female sexual dysfunction |
| 06/20/2002 | WO2002047678A1 Antilipemic agents |
| 06/20/2002 | WO2002047676A1 Topical composition and method for treating urinary stress incontinence |
| 06/20/2002 | WO2002047670A1 Treatment of male sexual dysfunction |
| 06/20/2002 | WO2002047669A1 Use of ep4 receptor agonists for treating neuropathic pain |
| 06/20/2002 | WO2002047668A2 Novel medicament compositions based on anticholinesterase drugs and on ciclesonides |
| 06/20/2002 | WO2002047667A2 Novel medicament compositions based on anticholinesterase drugs and on a steroid |
| 06/20/2002 | WO2002047663A1 Self emulsifying lipid matrix (selm) |
| 06/20/2002 | WO2002047662A2 Antibiotic/benzoyl peroxide dispenser |
| 06/20/2002 | WO2002047643A1 Water-free skin care formulations comprising micronized urea and method of manufacturing the same |
| 06/20/2002 | WO2002047612A2 Dietary supplement compositions |
| 06/20/2002 | WO2002047534A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 06/20/2002 | WO2002047493A2 Health promoting compositions |
| 06/20/2002 | WO2002034276A3 Use of the association of at least a plant extract of the genus camellia and of at least a carotenoid |
| 06/20/2002 | WO2002031110A3 Hematopoietic stem cell gene therapy |
| 06/20/2002 | WO2002030320A3 Stimulation of thymus for vaccination development |
| 06/20/2002 | WO2002022077A3 Compositions and methods for inhibition of hiv-1 infection |
| 06/20/2002 | WO2002012214A3 Non-imidazole aryloxyalkylamines as h3 receptor ligands |
| 06/20/2002 | WO2002011719A3 Lipase inhibitors for the treatment of dyspepsia |
| 06/20/2002 | WO2002008291A3 Multi-specific reagent for selective stimulation of cell surface receptors |
| 06/20/2002 | WO2002008226A3 Tricyclic 2-pyridone compounds useful as hiv reverse transcriptase inhibitors |
| 06/20/2002 | WO2002003911A8 Prevention and treatment of alzheimer's disease |
| 06/20/2002 | WO2002002085A3 Rapidly-decomposing administrable form for releasing active ingredients in the oral cavity or in bodily cavities |
| 06/20/2002 | WO2002000711A3 Ev-vegf nucleic acids and polypeptides and methods of use |
| 06/20/2002 | WO2002000208A3 Combination preparations of 3-n-formylhydroxylaminopropyl phosphonic acid derivatives or 3-n-acetylhydroxylaminopropyl phosphonic acid derivatives combined with specific pharmaceutical active agents |
| 06/20/2002 | WO2001098518A3 Biotransformation of biologically active compounds made of various classes of chemical substances by means of laccase and manganese peroxidase enzymes |
| 06/20/2002 | WO2001095831A3 Cardiac disease treatment and device |
| 06/20/2002 | WO2001094613A3 Methods and compounds for influencing beta3 integrin-dependent intracellular processes |
| 06/20/2002 | WO2001092876A3 Method for identifying compounds for modulating the activity of a tumour suppressor protein |
| 06/20/2002 | WO2001090139A3 A ligand for enhancing oral and cns delivery of biological agents |
| 06/20/2002 | WO2001089570A3 Combination of growth hormone secretagogues and antidepressants |
| 06/20/2002 | WO2001088104A3 Neural progenitor cell populations |
| 06/20/2002 | WO2001087977A3 Methods and compositions of matter concerning april/g70, bcma, blys/agp-3, and taci |
| 06/20/2002 | WO2001085942A3 Cytoskeleton-associated proteins |
| 06/20/2002 | WO2001085941A3 Myc targets |
| 06/20/2002 | WO2001085096A3 Mast cell regulation |
| 06/20/2002 | WO2001083524A3 Rna metabolism proteins |
| 06/20/2002 | WO2001078705A3 Compositions containing a naphthalmide and an antiproliferative agent |
| 06/20/2002 | WO2001078699A3 Use of bradycardiac substances in the treatment of myocardial diseases associated with hypertrophy and novel medicament combinations |
| 06/20/2002 | WO2001077113A3 Macrocyclic ns3-serine protease inhibitors of hepatitis c virus comprising n-cyclic p2 moieties |